Zacks Investment Research upgraded shares of CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. They currently have $2.75 price target on the biotechnology company’s stock.
According to Zacks, “Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company’s lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. “
NYSEAMERICAN CANF opened at $2.34 on Thursday. CAN-FITE BIOPHA/S has a 1-year low of $2.14 and a 1-year high of $25.95.
About CAN-FITE BIOPHA/S
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Featured Article: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with MarketBeat.com's FREE daily email newsletter.